SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to RemdesivirKanal Singh, Jason W. Van Winkle, Robin Dewar et al.|The Journal of Infectious Diseases|2024Cited by 13
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment TrialGail E. Potter, Pablo Tebas, Tyler Bonnett et al.|Annals of Internal Medicine|2022Cited by 6